When tech delivers clinical evidence at scale, it reduces the variability of care, according to Stacey Caywood, CEO of Wolters Kluwer Health.

The Centers for Medicare and Medicaid Services has issued a proposed rule to drive down prescription drug costs in Medicaid by increasing price transparency.  The rule would allow CMS to have more insight into what the most expensive drugs on the market actually cost to manufacture and distribute.  

Hospitals and health systems were optimistic about their financial performance to start the year, figuring that revenue and profit margins would rebound after a tough few years.

A nurse staffing bill in Minnesota, which exempted the Mayo Clinic, failed to get legislative approval on Monday.

Blue Cross Blue Shield of Massachusetts has added Tufts Medicine to its pay-for-equity financial payment model.  Blue Cross said it is the first health plan in Massachusetts — and among the first in the nation — to introduce contracts linking financial incentives to achieving measurable improvements in health equity.

There’s an increasing buzz among patients for GLP-1 weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy, but if patient demand continues to grow and Medicare expanded its coverage in response, it could cost the federal program between $13.6 and $26.8 billion annually.

IT, telehealth, clinical decision support, wellness tools and diagnostics all fall into the same category, says Jessica Hauflaire, COO of the Digital Therapeutics Alliance. Digital therapeutics consist of software as a direct intervention to treat, manage or prevent medical conditions.

The World Health Organization is calling for caution in using artificial intelligence-generated large language model tools (LLMs) such as ChatGPT, Bard, Bert and others that imitate understanding, processing and human communication.  LLMs increasing use for health-related purposes raises concerns for patient safety, WHO said. The precipitous adoption of untested systems could lead to errors by […]